Theravance Biopharma (TBPH) ($700MM market cap) introduced earlier this week their Section 3 trial evaluating ampreloxetine for the therapy of a uncommon illness didn’t meet its major endpoint and the corporate was winding down R&D efforts. The press launch has a variety of good nuggets in it that’ll be referencing. Again in November 2024, the corporate started a strategic overview with the hiring of Lazard as their monetary advisor. The overview on the floor would look like stale, but it surely reads as if a choice tree is in place depending on the outcomes of the ampreloxetine medical trial.
In reference to this announcement, the Strategic Evaluation Committee of the Theravance Biopharma Board of Administrators (the “Committee”) is accelerating its ongoing overview of alternate options to maximise worth for shareholders. Since its formation in 2024, the Committee has been engaged on an ongoing foundation with Lazard, its impartial monetary advisor, to consider alternatives out there to the Firm, together with underneath a number of potential outcomes for the CYPRESS examine. Constructing upon this work, the Committee will act with urgency to guage a broad vary of worth maximizing and tax environment friendly alternate options, together with however not restricted to a sale of the corporate.
If the trial failure was already totally contemplated and the strategic course of is not ranging from a standstill, issues may transfer fairly shortly from right here. Within the press launch, TBPH provides us all of the parts we have to provide you with a again of envelope estimate of its honest worth. Not like different busted biotech, TBPH has quite a lot of worthwhile belongings, this is not a typical melting ice dice, publish restructuring, will probably be money generative.
Money of $326.5 million at This autumn 2025 (no debt); roughly $400 million anticipated at finish of Q1 2026 together with receipt of 2025 milestones; Theravance extremely assured in attaining $100 million 2026 TRELEGY milestone
Trelegy is a blockbuster COPD and bronchial asthma therapy (partnered w/GSK) TBPH monetized by promoting their curiosity to Royalty Pharma (RPRX) in 2022 for $1.1B in upfront money plus some contingent milestone funds (they additional monetized Trelegy final yr by promoting some farther dated royalty funds to GSK for $225MM, however that is within the money stability quantity above). The remaining milestone cost TBPH is entitled to obtain from Royalty Pharma is printed within the 10-Q, which they describe as “extremely assured in attaining”:
With respect to 2026 TRELEGY world web gross sales, we’re eligible to obtain both (i) $50.0 million if Royalty Pharma receives $270.0 million or extra in royalty funds from GSK, which we might count on to happen within the occasion TRELEGY world web gross sales are roughly $3.16 billion or (ii) $100.0 million if Royalty Pharma receives $305.0 million or extra in royalty funds from GSK, which we might count on to happen within the occasion TRELEGY world web gross sales exceed roughly $3.51 billion. To attain the upper $100.0 million milestone in 2026, TRELEGY world web gross sales would require lower than a 2% improve over its 2024 world web gross sales.
Whole 2024 TRELEGY world web gross sales represented a 26% improve in comparison with 2023, and TRELEGY is presently anticipated to generate world peak gross sales of roughly $4.0 billion in 2026 based on consensus estimates. TRELEGY world web gross sales for the three and 9 months ended September 30, 2025 had been $979 million and $2.92 billion, respectively, which represented 24% and 13% year-over-year development, respectively.
As well as, TBPH additionally has a 35% curiosity in one other FDA accredited COPD therapy, Yupelri with accomplice Viatris (VTRS). It launched in 2019 and gross sales proceed to develop, though at a slowing tempo.
Collectively, the fee financial savings from the restructuring and continued gross sales from YUPELRI® are anticipated to consequence within the Firm producing roughly $60 to $70 million of annualized money move, beginning in Q3 2026. This money move projection is comprised of an estimated $45 to $55 million of Revenue from Operations (excluding non-cash share-based compensation) and projected Curiosity and Different Revenue, and doesn’t embrace potential earnings from the $100 million TRELEGY milestone.
Following the choice to wind down the ampreloxetine program, the Firm’s sources of worth embrace roughly $400 million of anticipated money on the finish of Q1 2026, a 35% curiosity in YUPELRI® that generates sturdy money move, and the potential TRELEGY milestone cost, in addition to Irish tax attributes.
The Irish tax attributes are described as following of their 10-Okay:
As of December 31, 2024, the Firm had Irish web working loss carryforwards of $1.17 billion and capital loss carryforwards of $60.9 million, each of which may be carried ahead indefinitely. The Firm has extra Irish tax attributes of $1.19 billion which primarily include unused capital allowances. Internet working losses and capital allowances can be utilized to offset future earnings from Irish entities and earnings associated to mental property.
I am simply going to assign no worth to the tax attributes, however definitely to the proper purchaser they’d be value one thing. The important thing variable is how a lot the Yupelri 35% stake is value, it does have patent safety out to 2039 however that has confronted some authorized challenges. The plain purchaser can be VTRS, they might notice price synergies, however for a finger within the air valuation, I’ll toss an 8x a number of on the mid-point of their earnings from operations steerage which incorporates their company overhead prices. I feel in all fairness conversative, however be at liberty to pushback for those who disagree.
Disclosure: I personal shares of TBPH